PULMICORT RESPULES: payments to doctors
Payments that named PULMICORT RESPULES as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $18K
- Providers
- 137
- Transactions
- 168
- Average per transaction
- $105
The per-transaction average — $105 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 137 providers the average total is $128, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astrazeneca UK Limited | $12,355 | 70.3% |
| AstraZeneca | $5,226 | 29.7% |